Lonza Group AG
SIX:LONN
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
325
587.4
|
Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one LONN stock under the Base Case scenario is 614.03 CHF. Compared to the current market price of 549.2 CHF, Lonza Group AG is Undervalued by 11%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Lonza Group AG
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for LONN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Lonza Group AG is a Swiss multinational company that specializes in the life sciences and advanced materials industries, making it an integral player in the global biotechnology and pharmaceutical landscapes. Founded in 1897, Lonza has evolved from a traditional chemical manufacturer to a leading contract development and manufacturing organization (CDMO) that partners with clients to accelerate the development of innovative therapies. The company offers a wide range of services, including biopharmaceutical manufacturing, cell and gene therapy solutions, and specialized expertise in microbial products and industrial bioprocessing. As pharmaceutical companies continue to explore complex biolog...
Lonza Group AG is a Swiss multinational company that specializes in the life sciences and advanced materials industries, making it an integral player in the global biotechnology and pharmaceutical landscapes. Founded in 1897, Lonza has evolved from a traditional chemical manufacturer to a leading contract development and manufacturing organization (CDMO) that partners with clients to accelerate the development of innovative therapies. The company offers a wide range of services, including biopharmaceutical manufacturing, cell and gene therapy solutions, and specialized expertise in microbial products and industrial bioprocessing. As pharmaceutical companies continue to explore complex biologics, Lonza stands out for its extensive technological capabilities and state-of-the-art facilities, positioning itself at the forefront of an industry that is rapidly transforming healthcare.
For investors seeking to understand Lonza's value proposition, it’s essential to appreciate the company's robust financial performance and strategic growth initiatives. Lonza has consistently demonstrated strong revenue growth, driven by its diversified portfolio and a commitment to research and development. The company has made significant investments in expanding its global manufacturing footprint, notably through the integration of advanced technology for efficient production processes. Furthermore, Lonza's strategic collaborations with major pharmaceutical enterprises in cell and gene therapies highlight its potential for sustained growth. As the world increasingly emphasizes innovation in the healthcare sector, Lonza Group AG remains well-poised to capitalize on emerging opportunities, making it an attractive prospect for investors looking to tap into the growing life sciences market.
Lonza Group AG is a Swiss multinational company known for its significant contributions to the life sciences sector. Its core business segments primarily focus on:
-
Pharma & Biotech:
- This segment provides a comprehensive range of services and technologies for the pharmaceutical and biotechnology industries. It includes the development and manufacturing of biologics, biosimilars, and small molecules. Services offered encompass drug substance and drug product development, as well as cell and gene therapy solutions.
-
Consumer Health:
- Lonza's Consumer Health segment focuses on products and solutions that enhance health and wellness, particularly in dietary supplements, personal care, and nutrition. This segment includes the production of active ingredients, formulations, and various health products.
-
Specialty Ingredients:
- In this segment, Lonza delivers specialized ingredients that serve diverse industries, including agriculture, personal care, and industrial applications. It encompasses antimicrobial solutions, performance ingredients, and other specialized chemicals that enhance product efficacy and safety.
-
Manufacturing Solutions:
- This segment offers technical and operational expertise in the production of complex products for customers across its various markets. It emphasizes high-quality manufacturing processes, emphasizing scalability and efficiency to meet client demands.
Overall, Lonza Group AG's core business segments reflect its commitment to innovation and technology, positioning itself as a leader in the life sciences and specialty chemicals sectors.
Lonza Group AG, a global leader in the life sciences industry, has several unique competitive advantages that strengthen its market position:
-
Wide Range of Capabilities: Lonza offers a comprehensive portfolio of services across the pharmaceutical and biotechnology sectors, including custom manufacturing, cell and gene therapies, and other specialty chemicals. This broad range of capabilities allows them to serve various customer needs and adapt to market changes.
-
Strong R&D Investment: The company places significant emphasis on research and development, enabling it to innovate continuously and maintain a leadership position in emerging technologies, particularly in areas like biologics and advanced therapies.
-
Strategic Partnerships: Lonza has established numerous strategic alliances with major pharmaceutical and biotech companies, which helps them secure long-term contracts and gain insights into future market trends. These partnerships often lead to collaborative R&D efforts and shared resources.
-
State-of-the-Art Facilities: The company invests heavily in modern, advanced manufacturing facilities that adhere to high-quality standards. This commitment to quality and efficiency not only reduces production costs but also enhances reliability and customer trust.
-
Regulatory Expertise: Lonza has extensive experience navigating the complex regulatory environments of the pharmaceutical industry. This expertise allows them to effectively manage compliance and expedite time-to-market for their clients’ products.
-
Global Reach with Local Expertise: Lonza boasts a global presence with operational facilities across multiple continents, allowing them to better meet the needs of international clients while also benefiting from local market intelligence and resources.
-
Strong Financial Position: Lonza's solid financial health enables it to invest in growth opportunities, whether through acquisitions, infrastructure improvements, or enhanced technology initiatives. This financial flexibility provides a competitive edge over smaller competitors.
-
Focus on Sustainability: Lonza is committed to sustainability and green chemistry initiatives, which not only appeal to socially-conscious investors and consumers but also position the company favorably in a market that is increasingly focused on environmental responsibility.
-
Talent and Expertise: Lonza attracts and retains top talent in the life sciences field, fostering a culture of innovation and excellence. Their workforce's expertise is a significant competitive advantage that enables them to deliver high-quality solutions.
-
Extensive Customer Relationships: The company’s long-standing relationships with key players in the pharmaceutical sector lead to repeat business and referrals, which are crucial for sustained growth.
By leveraging these competitive advantages, Lonza Group AG establishes a strong position within the life sciences market, enabling it to outperform its rivals.
Lonza Group AG, a prominent player in the life sciences industry, particularly in pharmaceuticals and biotechnology, faces several risks and challenges. Here are some key factors to consider:
-
Regulatory Compliance: The pharmaceutical industry is highly regulated, and changes in regulations, especially concerning drug manufacturing and safety standards, can pose significant risks. Non-compliance can lead to fines, recalls, or even shutdowns.
-
Supply Chain Disruptions: Global supply chain challenges, exacerbated by the COVID-19 pandemic, geopolitical tensions, and other macroeconomic factors, can lead to delays or shortages of raw materials. This is critical for a company like Lonza that relies on a complex supply network for its biopharmaceutical manufacturing.
-
Competition: The life sciences sector is highly competitive with both established companies and emerging biotech firms. Increased competition could lead to price wars and reduced margins. Keeping pace with innovation is crucial to maintaining market share.
-
Technological Advancements: Rapid developments in technology, such as gene therapy and personalized medicine, require constant innovation and adaptation. Lonza must invest heavily in R&D to stay at the forefront and not fall behind competitors who might adopt new technologies more swiftly.
-
Economic Factors: The broader economic environment can impact customer spending and investment in R&D. Economic downturns can lead to reduced budgets for pharmaceutical companies, which can impact Lonza's revenue.
-
Talent Acquisition and Retention: The life sciences industry requires highly skilled professionals. Competition for talent can be intense, and losing crucial personnel can impact operational effectiveness and innovation.
-
Geopolitical Risks: Trade tensions, tariffs, and other geopolitical issues can create uncertainty and volatility, affecting international operations and profitability.
-
Dependence on Key Customers: If Lonza has a concentrated customer base, losing a major client could significantly affect revenue. Diversification of its client portfolio is essential to mitigate this risk.
-
Intellectual Property Risks: Protecting intellectual property in a highly competitive and innovative field is crucial, as infringement or loss of proprietary technology can lead to significant competitive disadvantages.
By addressing these risks proactively, Lonza Group AG can better position itself for sustainable growth while navigating the challenges in the life sciences sector.
Revenue & Expenses Breakdown
Lonza Group AG
Balance Sheet Decomposition
Lonza Group AG
Current Assets | 4.9B |
Cash & Short-Term Investments | 1.4B |
Receivables | 1.4B |
Other Current Assets | 2.1B |
Non-Current Assets | 11.9B |
Long-Term Investments | 101m |
PP&E | 6.6B |
Intangibles | 4.7B |
Other Non-Current Assets | 488m |
Current Liabilities | 2.8B |
Accounts Payable | 468m |
Other Current Liabilities | 2.3B |
Non-Current Liabilities | 4.6B |
Long-Term Debt | 2.6B |
Other Non-Current Liabilities | 2B |
Earnings Waterfall
Lonza Group AG
Revenue
|
6.7B
CHF
|
Cost of Revenue
|
-4.7B
CHF
|
Gross Profit
|
2B
CHF
|
Operating Expenses
|
-1.1B
CHF
|
Operating Income
|
874m
CHF
|
Other Expenses
|
-301m
CHF
|
Net Income
|
573m
CHF
|
Free Cash Flow Analysis
Lonza Group AG
CHF | |
Free Cash Flow | CHF |
Lonza reported softer performance in Q1 2024 due to batch timing and weaker demand in some divisions. However, they maintain confidence in their full-year outlook with a flat constant currency revenue growth and CORE EBITDA margins between 27% and 29%. Strong commercial demand in Biologics and significant future growth from the Roche agreement are expected to drive H2 improvements. Ongoing projects, including new facilities in Switzerland, indicate progress. The company also advanced its share buyback program and confirmed Wolfgang Wienand as the new CEO starting in summer 2024.
What is Earnings Call?
LONN Profitability Score
Profitability Due Diligence
Lonza Group AG's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
Lonza Group AG's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
LONN Solvency Score
Solvency Due Diligence
Lonza Group AG's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Score
Lonza Group AG's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LONN Price Targets Summary
Lonza Group AG
According to Wall Street analysts, the average 1-year price target for LONN is 626.93 CHF with a low forecast of 328.25 CHF and a high forecast of 735 CHF.
Dividends
Current shareholder yield for LONN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
LONN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Lonza Group AG engages in the supply of pharmaceutical, healthcare and life science products. The company is headquartered in Basel, Basel-Stadt and currently employs 16,218 full-time employees. The company went IPO on 2002-04-03. The firm's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The firm divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
Contact
IPO
Employees
Officers
The intrinsic value of one LONN stock under the Base Case scenario is 614.03 CHF.
Compared to the current market price of 549.2 CHF, Lonza Group AG is Undervalued by 11%.